508. Bone Marrow Failure: Acquired: Poster III

An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System

Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics

High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone 1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Optimizing Complement Inhibitor Monitoring in PNH and Beyond

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase ...

Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab

Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Naïve Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Role of IRF-1 in Regulating the Proliferation and Function of Bone Marrow NK Cells in Patients with Severe Aplastic Anemia

The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Ran...

The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC